Literature DB >> 1420232

Infections in heart transplant recipients: the experience of the Italian heart transplantation program. Italian Study Group on Infections in Heart Transplantation.

P Grossi1, R De Maria, A Caroli, M S Zaina, L Minoli.   

Abstract

Infectious complications are an important cause of morbidity and mortality in heart transplantation. In this report we describe their incidence in the Italian Heart Transplantation Program and their relationship to induction immunosuppressive protocols used. A total of 662 heart transplantations in 651 patients had been performed by March 1, 1990, in 10 Italian centers, with a follow-up of 12,022 patient-months. Actuarial survival at 54 months was 80%. There were 115 deaths, 28 as a result of infection (24%); 30 were perioperative. Mortality from infection was 15% in the first 30 postoperative days and 35% thereafter. During follow-up, 256 life-threatening infectious episodes occurred in 180 patients, for a mean of 1.42 infections/patient. Of these episodes, 28 (10.9%) were lethal. The rate at 54 months, excluding perioperative deaths, was 0.021 episodes/patient-month, with a mean of 0.39 infections/patient in the 651-patient series. At 6 months, 72% of patients were free from infection. This value did not change significantly during subsequent follow-up. Bacterial infections were most frequent (49.2%); fungal (10.5%) and protozoan (5.9%) infections had the worst outcome (lethality 26% and 20%, respectively). A primary cytomegalovirus infection was observed in 23 cases (12 mismatches). Lung involvement (99 episodes) and bacterial sepsis (47 episodes) were most common. Eighty episodes of infection (31.2%) were preceded by a supplementary treatment for rejection with steroid pulses (69%), prednisone boost (20%), or cytolytic therapy (11%). Treatment had preceded the infection by less than 15 days in 55% of cases.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1420232

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  7 in total

Review 1.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 2.  Infections in solid-organ transplant recipients.

Authors:  R Patel; C V Paya
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

3.  Risk factors for invasive fungal disease in heart transplant recipients.

Authors:  Alexander S Rabin; Michael M Givertz; Gregory S Couper; Margaret M Shea; Driele Peixoto; Deborah S Yokoe; Lindsey R Baden; Francisco M Marty; Sophia Koo
Journal:  J Heart Lung Transplant       Date:  2014-10-02       Impact factor: 10.247

4.  Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. British Society for Medical Mycology.

Authors:  D W Denning; E G Evans; C C Kibbler; M D Richardson; M M Roberts; T R Rogers; D W Warnock; R E Warren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-06       Impact factor: 3.267

5.  Pneumocystis carinii pneumonia in heart transplant recipients.

Authors:  P Grossi; G B Ippoliti; C Goggi; P Cremaschi; M Scaglia; L Minoli
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

6.  Impact of animal strain on gene expression in a rat model of acute cardiac rejection.

Authors:  Katherine J Deans; Peter C Minneci; Hao Chen; Steven J Kern; Carolea Logun; Sara Alsaaty; Kelly J Norsworthy; Stephanie M Theel; Joel D Sennesh; Jennifer J Barb; Peter J Munson; Robert L Danner; Michael A Solomon
Journal:  BMC Genomics       Date:  2009-06-24       Impact factor: 3.969

7.  Infectious complications following heart transplantation in the era of high-priority allocation and extracorporeal membrane oxygenation.

Authors:  Stéphanie Pons; Romain Sonneville; Lila Bouadma; Lenka Styfalova; Stéphane Ruckly; Mathilde Neuville; Aguila Radjou; Jordane Lebut; Marie-Pierre Dilly; Bruno Mourvillier; Richard Dorent; Patrick Nataf; Michel Wolff; Jean-François Timsit
Journal:  Ann Intensive Care       Date:  2019-01-25       Impact factor: 6.925

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.